Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF-mutated melanomas. (ASCO 2011, Plenary Session, Abstract LBA4)

Research output: Contribution to journalArticlepeer-review

  • External authors:
  • P. B. Chapman
  • A. Hauschild
  • C. Robert
  • J. M. G. Larkin
  • J. B. A. G. Haanen
  • A. Ribas
  • D. Hogg
  • S. O'Day
  • P. A. Ascierto
  • A. Testori
  • R. Dummer
  • J. A. Sosman
  • C. Garbe
  • R. J. Lee
  • K. B. Nolop
  • B. Nelson
  • J. Hou
  • K. T. Flaherty
  • G. A. McArthur

Bibliographical metadata

Original languageEnglish
Pages (from-to)LBA4-LBA4
Number of pages1
JournalJournal of Clinical Oncology
Volume29
Issue numberSupplement 15
DOIs
Publication statusPublished - 20 May 2011